One study showed that HDGC patients without a known CDH1 mutation diagnosed by multigene cancer panel before surgery were more likely to have metastatic disease and die of their disease than were patients with known CDH1 mutation status (Moslim et al., 2018), suggesting that genetic counseling and detection of CDH1 mutations in asymptomatic carriers improves HDGC patient survival. The gene discussed is CDH1; the disease is cancer.